A CRISPR-Cas12a-based specific enhancer for more sensitive detection of SARS-CoV-2 infection
Weiren Huang,Lei Yu,Donghua Wen,Dong Wei,Yangyang Sun,Huailong Zhao,Yu Ye,Wei Chen,Yongqiang Zhu,Lijun Wang,Li Wang,Wenjuan Wu,Qianqian Zhao,Yong Xu,Dayong Gu,Guohui Nie,Dongyi Zhu,Zhongliang Guo,Xiaoling Ma,Liman Niu,Yikun Huang,Yuchen Liu,Bo Peng,Renli Zhang,Xiuming Zhang,Dechang Li,Yang Liu,Guoliang Yang,Lanzheng Liu,Yunying Zhou,Yunshan Wang,Tieying Hou,Qiuping Gao,Wujiao Li,Shuo Chen,Xuejiao Hu,Mei Han,Huajun Zheng,Jianping Weng,Zhiming Cai,Xinxin Zhang,Fei Song,Guoping Zhao,Jin Wang
DOI: https://doi.org/10.1016/j.ebiom.2020.103036
IF: 11.205
2020-11-01
EBioMedicine
Abstract:BACKGROUND: Real-time reverse transcription-PCR (rRT-PCR) has been the most effective and widely implemented diagnostic technology since the beginning of the COVID-19 pandemic. However, fuzzy rRT-PCR readouts with high Ct values are frequently encountered, resulting in uncertainty in diagnosis.METHODS: A Specific Enhancer for PCR-amplified Nucleic Acid (SENA) was developed based on the Cas12a trans-cleavage activity, which is specifically triggered by the rRT-PCR amplicons of the SARS-CoV-2 Orf1ab (O) and N fragments. SENA was first characterized to determine its sensitivity and specificity, using a systematic titration experiment with pure SARS-CoV-2 RNA standards, and was then verified in several hospitals, employing a couple of commercial rRT-PCR kits and testing various clinical specimens under different scenarios.FINDINGS: The ratio (10 min/5 min) of fluorescence change (FC) with mixed SENA reaction (mix-FCratio) was defined for quantitative analysis of target O and N genes, and the Limit of Detection (LoD) of mix-FCratio with 95% confidence interval was 1.2≤1.6≤2.1. Totally, 295 clinical specimens were analyzed, among which 21 uncertain rRT-PCR cases as well as 4 false negative and 2 false positive samples were characterized by SENA and further verified by next-generation sequencing (NGS). The cut-off values for mix-FCratio were determined as 1.145 for positive and 1.068 for negative.INTERPRETATION: SENA increases both the sensitivity and the specificity of rRT-PCR, solving the uncertainty problem in COVID-19 diagnosis and thus providing a simple and low-cost companion diagnosis for combating the pandemic.FUNDING: Detailed funding information is available at the end of the manuscript.
medicine, research & experimental